research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
Search
for
Sort by
Research
960-990 / 1000+ results research Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
research Expression and Activity Assay of Human Steroid 5 Alpha-Reductase Type II in CHO Cells
Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
research PROSPECTIVE EVALUATION ON SEXUAL DYSFUNCTION PERSISTENCE, WORSENING OR IMPROVEMENT IN BPH PATIENTS AFTER FINASTERIDE OR DUTASTERIDE TREATMENT
Finasteride and dutasteride can affect sexual function in BPH patients.
research The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
research Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
research Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
5-Alpha-Reductase Inhibitors can cause negative side effects.
![Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1](/images/assets/ff6e6cbe-cb9c-4d11-87ef-671d28ffd4fa/small/15506.jpg)
research Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1
Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
research Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy
Finasteride blocks progesterone's effect on absence seizures in rats.
research Psychiatric and sexual dysfunction warnings strengthened for finasteride and dutasteride
Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
research Contraindicated use of 5-alpha-reductase inhibitors in women
The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride
Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.
research Epigenetic Effects of Finasteride on Human Leydig Cells
Finasteride may cause lasting sexual issues by altering specific genes in human cells.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research finasteride, n.
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Repurposing Finasteride and Serotonin Reuptake Inhibitors as Novel Antimicrobials: A Dual-Action Approach to Target Bacterial and Fungal Pathogens
Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
research Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway
DA-9401 can protect against finasteride-induced reproductive damage in rats.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Studies on the stability of finasteride sustained-release tablets
Finasteride sustained-release tablets are stable.
research Editorial Comment
More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
research 5α-reductase inhibitors/finasteride
Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
research Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal Inhibitors of Rat 5α-Reductase
Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
research Antiandrogenic activity of Riboflavin 5′-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines
Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.